Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth
David J. Dowling, … , Pyone Pyone Aye, Ofer Levy
David J. Dowling, … , Pyone Pyone Aye, Ofer Levy
Published March 23, 2017
Citation Information: JCI Insight. 2017;2(6):e91020. https://doi.org/10.1172/jci.insight.91020.
View: Text | PDF
Research Article Vaccines

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth

  • Text
  • PDF
Abstract

Infection is the most common cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, newborns fail to respond optimally to most vaccines. Adjuvantation is a key approach to enhancing vaccine immunogenicity, but responses of human newborn leukocytes to most candidate adjuvants, including most TLR agonists, are functionally distinct. Herein, we demonstrate that 3M-052 is a locally acting lipidated imidazoquinoline TLR7/8 agonist adjuvant in mice, which, when properly formulated, can induce robust Th1 cytokine production by human newborn leukocytes in vitro, both alone and in synergy with the alum-adjuvanted pneumococcal conjugate vaccine 13 (PCV13). When admixed with PCV13 and administered i.m. on the first day of life to rhesus macaques, 3M-052 dramatically enhanced generation of Th1 CRM-197–specific neonatal CD4+ cells, activation of newborn and infant Streptococcus pneumoniae polysaccharide–specific (PnPS-specific) B cells as well as serotype-specific antibody titers, and opsonophagocytic killing. Remarkably, a single dose at birth of PCV13 plus 0.1 mg/kg 3M-052 induced PnPS-specific IgG responses that were approximately 10–100 times greater than a single birth dose of PCV13 alone, rapidly exceeding the serologic correlate of protection, as early as 28 days of life. This potent immunization strategy, potentially effective with one birth dose, could represent a new paradigm in early life vaccine development.

Authors

David J. Dowling, Simon D. van Haren, Annette Scheid, Ilana Bergelson, Dhohyung Kim, Christy J. Mancuso, Willemina Foppen, Al Ozonoff, Lynn Fresh, Terese B. Theriot, Andrew A. Lackner, Raina N. Fichorova, Dmitri Smirnov, John P. Vasilakos, Joe M. Beaurline, Mark A. Tomai, Cecily C. Midkiff, Xavier Alvarez, James L. Blanchard, Margaret H. Gilbert, Pyone Pyone Aye, Ofer Levy

×

Figure 1

Unlike R848, the lipidated, locally acting TLR7/8 agonist 3M-052 demonstrates low serum distribution and little systemic cytokine induction.

Options: View larger image (or click on image) Download as PowerPoint
Unlike R848, the lipidated, locally acting TLR7/8 agonist 3M-052 demonst...
(A) The structure of R848 (resiquimod) and 3M-052, a TLR7/8 activating imidazoquinoline bearing a C18 lipid moiety and designed for slow dissemination from the site of injection. (B and C) Rodent pharmacokinetic and pharmacodynamic studies. Serum drug levels were measured by LC-MS/MS at the indicated times before or after dose in rats following a single i.m. (into quadriceps) or s.c. (into scruff of neck) administration of 3M-052 or R848 formulated in oil-in-water (O/W) emulsion (vehicle). The results represent median serum drug levels and induced TNF at each time point for each dose (n = 5). (D) Evaluation of s.c. mouse serum cytokine kinetics after a single dose of 3M-052 or R848 (both 1 mg/kg, 20 μg/mouse) formulated in O/W emulsion (vehicle) (n = 3).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts